Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBITDA Margin (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed EBITDA Margin for 12 consecutive years, with 608.89% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 55641.0% year-over-year to 608.89%, compared with a TTM value of 873.87% through Dec 2025, up 29260.0%, and an annual FY2025 reading of 873.87%, up 29260.0% over the prior year.
  • EBITDA Margin was 608.89% for Q4 2025 at Agios Pharmaceuticals, up from 907.37% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 608.89% in Q4 2025 and bottomed at 12156.85% in Q1 2022.
  • Average EBITDA Margin over 4 years is 2068.27%, with a median of 1295.97% recorded in 2023.
  • The sharpest move saw EBITDA Margin soared 1054136bps in 2023, then plummeted -9763bps in 2025.
  • Year by year, EBITDA Margin stood at 2300.97% in 2022, then surged by 35bps to 1496.23% in 2023, then grew by 22bps to 1165.3% in 2024, then soared by 48bps to 608.89% in 2025.
  • Business Quant data shows EBITDA Margin for AGIO at 608.89% in Q4 2025, 907.37% in Q3 2025, and 1020.12% in Q2 2025.